Abstract: A hydraulic system including a secondary pressure regulating transmission control system and a hydraulic power-supply system is provided. The secondary pressure regulating transmission control system includes a first hydraulic control system, a second hydraulic control system, and a third hydraulic control system. An integrated electro-hydraulic actuator of the first hydraulic control system is mounted on a first hydraulic cylinder, the integrated electro-hydraulic actuator of the second hydraulic control system is mounted on a second hydraulic cylinder, and the integrated electro-hydraulic actuator of the third hydraulic control system is mounted on a third hydraulic cylinder. The first hydraulic control system is configured to control a movable arm, the second hydraulic control system is configured to control a stick, and the third hydraulic control system is configured to control a bucket.

Abstract: Provided is a system for electro-hydraulic control of hydraulic pipeline rupture protection based on differential pressure feedback, which relates to the field of hydraulic control technology. The system comprises a hydraulic actuation system and a controller system. The controller system comprises a differential pressure feedback loop and a flow rate diagnostic loop. The differential pressure feedback loop is configured to obtain a flow rate signal within a hydraulic pipeline and determine a proportional signal. The flow rate diagnostic loop is configured to receive the proportional signal, and in response to determining that a duration for which the proportional signal remains outside a threshold range reaches a preset safety duration, cut off an actuating end of the hydraulic actuation system to achieve pipeline rupture protection.

Abstract: Disclosed in the present invention is a compound as represented by formula (IA) or formula (IC) or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. The definition of each group in the formula is shown in the description for details. Further disclosed are a pharmaceutical composition containing the compound and the use thereof in the preparation of a drug for preventing and/or treating diseases or conditions related to HPK1 activity.

Abstract: An atomizing device includes a housing, an end lid and a cover. The end lid is disposed at an end of the housing, and is hermitically connected with the housing. The cover is disposed to cover around the end lid. A first conducting groove is disposed to extend circumferentially at a selective one of an outer wall of the end lid and an inner wall of the cover. A second conducting groove is spatially communicated with the first conducting groove, and an included angle is formed between the first conducting groove and the second conducting groove. A sliding piece is disposed at the rest of the outer wall of the end lid and the inner wall of the cover to mate with the first conducting groove and the second conducting groove. The sliding piece is disposed to move in the first conducting groove and the second conducting groove.

Abstract: A compound having HPK1 inhibitory activity as shown in formula (IA) or (IC), and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and use of same in preparation of a drug for preventing and/or treating diseases or conditions associated with HPK1 activity.

Abstract: The present disclosure discloses a recombinant varicella-zoster virus (VZV) vaccine, including a fusion protein formed by an amino acid sequence of an extracellular domain of a recombinant glycoprotein gE of a live attenuated VZV strain (OKA strain) gene and an Fc fragment of human immunoglobulin. The present disclosure further provides preparation and use of the fusion protein, a corresponding recombinant gene, a eukaryotic expression vector, etc. The fusion protein of the present disclosure has prominent immunogenicity and can induce the high-level expression of neutralizing antibodies in serum.

Abstract: Provided are a fused tricyclic compound having the structure shown in formula (I), a pharmaceutical composition thereof, and a use thereof. The fused tricyclic compound serves as a selective inhibitor of KRAS mutation, and has high activity, good selectivity. and reduced toxic side effects.

Abstract: The present disclosure discloses a recombinant varicella-zoster virus (VZV) vaccine, including a fusion protein formed by an amino acid sequence of an extracellular domain of a recombinant glycoprotein gE of a live attenuated VZV strain (OKA strain) gene and an Fc fragment of human immunoglobulin. The present disclosure further provides preparation and use of the fusion protein, a corresponding recombinant gene, a eukaryotic expression vector, etc. The fusion protein of the present disclosure has prominent immunogenicity and can induce the high-level expression of neutralizing antibodies in serum.

Abstract: An atomizing device includes a housing, an end lid and a cover. The end lid is disposed at an end of the housing, and is hermitically connected with the housing. The cover is disposed to cover around the end lid. A first conducting groove is disposed to extend circumferentially at a selective one of an outer wall of the end lid and an inner wall of the cover. A second conducting groove is spatially communicated with the first conducting groove, and an included angle is formed between the first conducting groove and the second conducting groove. A sliding piece is disposed at the rest of the outer wall of the end lid and the inner wall of the cover to mate with the first conducting groove and the second conducting groove. The sliding piece is disposed to move in the first conducting groove and the second conducting groove.

Abstract: An oxaazaquinazolin-7(8H)-ketone compound with a selective inhibition effect on KRAS gene mutation and pharmaceutically acceptable salts thereof, stereoisomers, solvent compounds or prodrugs (as shown in formula I or formula II, see the details of the definition to each group in the formulas in the specification), as well as the pharmaceutical composition containing the compound, and the application thereof in preparation of cancer medicine.

Abstract: A phosphorus-based calcification inhibitor (“inhibitor”) configured to prevent calcification of anaerobic granular sludge.

Abstract: The present invention relates to the treatment of a tumor selected from the group consisting of pancreatic cancer, liver cancer, melanoma, colon cancer, glioblastoma, osteosarcoma, prostate cancer and breast cancer, more particularly pancreatic cancer. The inventors found a novel family compounds of formula (I) able to treat a variety of cancers by inhibiting NUPR1, a stress-inducible 82-amino-acid-long, intrinsically disordered member of the AT-hook family of chromatin proteins. Thus, the present invention relates to a compound of formula (I) for its use in the treatment of a tumor selected from the group consisting of pancreatic cancer, liver cancer, melanoma, colon cancer, glioblastoma, osteosarcoma, prostate cancer and breast cancer. In particular, the inventors tested compounds of formula (I) on four well characterized primary pancreatic cancer-derived cells 02.

Abstract: The present invention belongs to the technical field of wastewater treatment, and particularly relates to a method for pre-conditioning high-calcium wastewater by calcification blocking, and a device for implementing the method. The method for treating high-calcium wastewater by calcification blocking includes mixing high-calcium wastewater, an alkalizing agent and a chelating agent, and carrying out alkalizing conditioning pretreatment under a condition of stirring by bubbling of a biogas, so as to obtain pre-conditioned wastewater. The pre-conditioned wastewater is mixed with anaerobic granular sludge, and an anaerobic reaction is performed in a high hydraulic shear flow field formed by the biogas, so as to generate the biogas and calcium scale. A part of the biogas for the stirring is refluxed by bubbling of the biogas and the rest of the biogas is refluxed for forming the high hydraulic shear flow field.

Abstract: Embodiments of the present invention pertain to a composite decalcification agent of calcified anaerobic granular sludge and a decalcification regeneration process.

Abstract: A phosphorus-based calcification inhibitor (“inhibitor”) configured to prevent calcification of anaerobic granular sludge.

Abstract: Embodiments of the present invention pertain to a composite decalcification agent of calcified anaerobic granular sludge and a decalcification regeneration process.

Abstract: The invention pertains to amphiphilic dendrimers complexed with Bcl3 siRNA. The amphiphilic dendriplexes described herein are biodegradable and exhibit enhanced siRNA delivery. The amphiphilic dendriplexes containing Bcl3 siRNA inhibit cancer cell/tumor growth in vitro and in vivo without toxicity. Accordingly, an embodiment of the invention provides a method of treating a cancer, particularly, nasopharyngeal carcinoma, by administering to a subject in need thereof, a therapeutic amount of amphiphilic dendrimers complexed with Bcl3 siRNA. Pharmaceutical compositions containing the amphiphilic dendrimers complexed with Bcl3 siRNA are also provided.

Abstract: The present disclosure provides a method and an apparatus for synchronous lighting control by a mobile terminal. The method comprises acquiring a loading program of each of a plurality of lamps required to be synchronously controlled; acquiring a state of each of the plurality of lamps according to the loading program; grouping the plurality of lamps according to the state of each of the plurality of lamps; and controlling a switching and a color of each of the plurality of lamps synchronously according to the grouping. A beneficial effect of the present disclosure is that by grouping the smart lamps, the smart lamps are managed in batch, and by using a colorful scene and a changing music to control a switching and a color of the smart lamps, the intelligence level of the system is improved, the control style is enriched, and the user experience is better.